Genezen Announces Strategic Process Development and Manufacturing Partnership Agreement with Seattle Children’s Research Institute for X-linked Agammaglobulinemia (XLA) Cell Therapy Program

Posted on by

Seattle Children’s Research Institute will be one of Genezen’s first customers to leverage its cutting-edge Cytegrity™ technology from biotech leader CSL for stable and scalable high-titer lentivirus production. FISHERS, Ind., March 6, 2024 /PRNewswire/ — Seattle Children’s Research…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.